Related references
Note: Only part of the references are listed.Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Eirini Pectasides et al.
CANCER DISCOVERY (2018)
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma
Smita S. Joshi et al.
FUTURE ONCOLOGY (2018)
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
Steven B. Maron et al.
CANCER DISCOVERY (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al.
LANCET ONCOLOGY (2018)
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).
Smita Suhas Joshi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating tumor DNA (ctDNA) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEC).
Steven Brad Maron et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
Seyoung Seo et al.
ONCOTARGET (2017)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Novel Targeted Therapies for Esophagogastric Cancer
Steven B. Maron et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2017)
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2017)
Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+gastric cancer.
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V. T. Catenacci et al.
GASTRIC CANCER (2016)
FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors.
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
Soomin Ahn et al.
MODERN PATHOLOGY (2016)
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson et al.
CANCER DISCOVERY (2016)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro et al.
LANCET ONCOLOGY (2015)
Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies
Siraj M. Ali et al.
ONCOLOGIST (2015)
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
Daniel V. T. Catenacci
MOLECULAR ONCOLOGY (2015)
FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
X. Su et al.
BRITISH JOURNAL OF CANCER (2014)
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) Study
Rosine Guimbaud et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Waddell et al.
ANNALS OF ONCOLOGY (2013)
FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie et al.
CLINICAL CANCER RESEARCH (2013)
Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
Amikar Sehdev et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
FGFR2 gene amplification and clinicopathological features in gastric cancer
K. Matsumoto et al.
BRITISH JOURNAL OF CANCER (2012)
Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
Eun-Jung Jung et al.
HUMAN PATHOLOGY (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
Ailin Bai et al.
CANCER RESEARCH (2010)
Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
Wei-meng Zhao et al.
CLINICAL CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival
Kaiko Kunii et al.
CANCER RESEARCH (2008)
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
M. Hofmann et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Share Paper
